Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: A randomized trial

Journal of Clinical Psychiatry

Volumn 76, Issue 10, 2015, Pages 1359-1365

  Green, Alan I ^a   Brunette, Mary F ^a   Dawson, Ree ^b   Buckley, Peter ^c   Wallace, Amy E ^d   Hafez, Hisham ^a   Herz, Marvin ^e   Narasimhan, Meera ^f   Noordsy, Douglas L ^a   O'Keefe, Christopher ^a   Sommi, Roger W ^g   Steinbook, Richard M ^e   Weeks, Marjorie ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; LONG ACTING DRUG; OLANZAPINE; RISPERIDONE; DELAYED RELEASE FORMULATION; NEUROLEPTIC AGENT;

ADULT; AFRICAN AMERICAN; ALCOHOL ABUSE; ALCOHOL USE DISORDER; ALCOHOLISM; BARNES AKATHISIA SCALE; CANNABIS USE; CAUCASIAN; CLINICAL GLOBAL IMPRESSION SCALE; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM DISEASE; DOPAMINE RECEPTOR BLOCKING; DRINKING BEHAVIOR; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DSM-IV; EDUCATION; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; HYPERSALIVATION; INTENTION TO TREAT ANALYSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MARRIAGE; NAUSEA; NEUROLOGIC DISEASE; PAIN; PATIENT COMPLIANCE; PATIENT COUNSELING; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STEADY STATE; STOMACH DISCOMFORT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; COMPARATIVE STUDY; COMPLICATION; DELAYED RELEASE FORMULATION; ORAL DRUG ADMINISTRATION; PSYCHOLOGIC TEST; PSYCHOLOGICAL RATING SCALE;

ADMINISTRATION, ORAL; ADULT; ALCOHOLISM; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; MALE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA;

EID: 84945385833     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.13m08838     Document Type: Conference Paper

References (31)

1. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264(19):2511-2518.
2. Wade D, Harrigan S, Edwards J, et al. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry. 2006;189(3):229-234.
3. Drake RE, O'Neal EL, Wallach MA. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat. 2008;34(1):123-138.
4. Xie H, McHugo GJ, Fox MB, et al. Substance abuse relapse in a ten-year prospective follow-up of clients with mental and substance use disorders. Psychiatr Serv. 2005;56(10):1282-1287.
5. Zhornitsky S, Rizkallah E, Pampoulova T, et al. Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J Clin Psychopharmacol. 2010;30(4):417-424.
6. Buckley P, McCarthy M, Chapman P, et al. Clozapine treatment of comorbid substance abuse in patients with schizophrenia. Schizophr Res. 1999;36:272.
7. Green AI, Burgess ES, Dawson R, et al. Alcohol and cannabis use in schizophrenia: effects of clozapine vs risperidone. Schizophr Res. 2003;60(1):81-85.
8. Lee ML, Dickson RA, Campbell M, et al. Clozapine and substance abuse in patients with schizophrenia. Can J Psychiatry. 1998;43(8):855-856.
9. Brunette MF, Drake RE, Xie H, et al. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull. 2006;32(4):637-643.
10. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26(2):441-449.
11. Brunette MF, Dawson R, O'Keefe CD, et al. A randomized trial of clozapine vs other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagn. 2011;7(1-2):50-63.
12. Green AI, Zimmet SV, Strous RD, et al. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry. 1999;6(6):287-296.
13. Green AI, Noordsy DL, Brunette MF, et al. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat. 2008;34(1):61-71.
14. Nesvåg R, Hendset M, Refsum H, et al. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand. 2006;114(1):21-26.
15. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis-I Disorders- Patient Edition (SCID-I/P, Version 2.0). New York, NY: Biometrics Research Department; 1996.
16. Sobell LC, Sobell MB. Timeline Follow-Back: a technique for assessing self-reported alcohol consumption. In: Litten RZ, Allen J, eds. Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, NJ: Humana Press; 1992:41-72.
17. McHugo GJ, Drake RE, Burton HL, et al. A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. J Nerv Ment Dis. 1995;183(12):762-767.
18. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
19. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education and Welfare; 1976.
20. Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33(6):766-771.
21. Wang JS, Ruan Y, Taylor RM, et al. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol. 2004;7(4):415-419.
22. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;45(s212):11-19.
23. Lane RD, Glazer WM, Hansen TE, et al. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis. 1985;173(6):353-357.
24. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672-676.
25. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38(4):963-974.
26. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909.
27. West JC, Marcus SC, Wilk J, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull. 2008;34(5):995-1001.
28. Riedel M, Schwarz MJ, Strassnig M, et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci. 2005;255(4):261-268.
29. Darby JK, Pasta DJ, Elfand L, et al. Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol. 1997;17(6):478-484.
30. Uchida H, Mamo DC, Kapur S, et al. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry. 2008;69(8):1281-1286.
31. Chau DT, Ahmed J, Wang TT, et al. Raclopride lessens the ability of clozapine to suppress alcohol drinking in Syrian golden hamsters. Neuropharmacology. 2011;61(4):646-652.